Publishing Details
About This Podcast
Explore Statistics
Recent Episodes
Moderna in 2026: What the Wins and Losses Are Telling Us
Subscribe to Biotech Blueprint for free at biotechblueprint.comIn the latest joint podcast episode by Biotech Blueprint × Biotech Capital Compass, we zoom in on Moderna and where the company stands…
FDA Shifts to One Pivotal Trial and Moderna Flu Shot Back Under FDA Review – This Week in Biotech #90
Subscribe to Biotech Blueprint for free at biotechblueprint.com.
Hims Launches Compounded GLP-1 Pill, CVS Forces Biosimilars – This Week in Biotech #88
Compounded semaglutide draws FDA scrutiny as Novo Nordisk guides 2026 lower and Eli Lilly leans into a $50 Medicare copay (Jan 30-Feb 5, 2026).Follow Biotech Blueprint at biotechblueprint.com.
Regenxbio FDA Hold, Sanofi Vaccine Demand Softness, and CMS Negotiation Expansion – This Week in Biotech #87
FDA pauses two AAV programs, Sanofi reports US vaccine uptake slipping, and CMS widens negotiations to more blockbuster drugs (Jan 23-29, 2026).Subscribe to Biotech Blueprint at biotechblueprint.com.
Moderna Merck V940 Shows Five Year Melanoma Durability, Biopharma Deal Activity Picks Up
This Week in Biotech #86. Subscribe to Biotech Blueprint for free at biotechblueprint.com. KEYNOTE-942 durability, plus GSK’s $2.2B RAPT food allergy deal, BMS partners with Janux, Corcept's overall…
#CDC #Vaccine Schedule Shifts, Practice-Changing Phase 3 Wins, and Deal Heat – This Week in Biotech #84
Subscribe to This Week in Biotech for free at biotechblueprint.com.
Inside NImmune’s Phase 3 Push in Ulcerative Colitis
I sat down with NImmune CEO Josep Bassaganya-Riera to talk about omilancor, their gut-restricted oral IBD drug now in Phase 3 clinical trials. We cover LANCL2 biology, their biomarker aimed at…
FDA Tightens Vaccine Pathways, Medicare Slashes Drug Prices — This Week in Biotech #80
Plus Duchenne’s landmark phase 3 win, a survival boost in glioblastoma, motion sickness momentum at Vanda, and ACIP’s newborn vaccine chaos (Nov 21-Dec 4, 2025).Subscribe to Biotech Blueprint for…
CDC’s Autism Reversal Shocks Experts, mRNA Flu Shot Advances, Big Oncology Wins - This Week in Biotech #79
Subscribe to Biotech Blueprint at biotechblueprint.com
FDA Opens New Pathway, Pfizer’s $10B GLP-1 Win, and Biotech’s Return to Offense — This Week in Biotech #78
Subscribe to Biotech Blueprint for free at biotechblueprint.com. A week of rare regulatory momentum, strategic M&A, and meaningful clinical wins.
Inside Sensible Biotechnologies: Reinventing mRNA Manufacturing
Subscribe to Biotech Blueprint at biotechblueprint.com In today's episode:How an Oxford-born, YC-backed startup is betting that cell-based production will define mRNA’s next decade.
Trump Reshapes Obesity Drug Prices, Novo Tops Pfizer Again — This Week in Biotech #77
Subscribe to Biotech Blueprint for free at biotechblueprint.com.Pfizer’s courtroom gamble to block Novo Nordisk’s $10B Metsera takeover failed, and Novo immediately fired back with an even higher…
Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build — This Week in Biotech #76
Subscribe to Biotech Blueprint newsletter for free at biotechblueprint.com.
Drug launch prices soar; mRNA shots linked to longer cancer survival — This Week in Biotech #75
Subscribe to Biotech Blueprint for FREE at biotechblueprint.com.
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer
Subscribe to Biotech Blueprint for free at biotechblueprint.com. About this episode: mRNA’s next chapter isn’t just flu and COVID. We break down why latent viruses (CMV, EBV, HSV) persist, why T…
Trump cuts IVF & Medicaid drug prices; Novo buys Omeros; Lilly's GLP-1 orforglipron shines — This Week in Biotech #74
Subscribe at biotechblueprint.com.
Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech #72 Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech #72
Read the full edition or subscribe to Biotech Blueprint herehttps://www.biotechblueprint.com/p/pharma-tariffs-on-ice-fda-limits?r=474vk1
ACIP votes, Roche-89bio deal, Regeneron’s FOP win — This Week in Biotech #70
Subscribe to Biotech Blueprint newsletter for free at biotechblueprint.com/embed
The mRNA Revolution: Beyond COVID to Cancer, Flu and Herpes Vaccines
Welcome to Biotech Blueprint. If you want to subscribe to a free weekly biotech/pharma newsletter, you can do so here: https://www.biotechblueprint.com/embed In this special episode, I teamed up…
Novo’s Layoffs, Novartis’ $1.4B Buy, Pancreatic Cancer Progress — This Week in Biotech #69
Subscribe to Biotech Blueprint, your free biotech & pharma newsletter released every Friday at biotechblueprint.com
Frequently Asked Questions
Biotech Blueprint has published 43 episodes since May 2025, covering topics in Technology.
Biotech Blueprint is currently highly active with new episodes weekly. Average episode length is 6m.
